Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft report obtained by STAT.

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 diabetes and Wegovy for obesity but is coming under competitive pressure from rival therapies from Eli Lilly based on dual GIP/GLP-1 agonist tirzepatide.

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% jump in the Danish drugmaker’s share price in premarket trading.

A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the competitive field.

Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here.

Danish healthcare company Novo Nordisk A/S (NVO) announced topline results from a phase 1b/2a clinical trial with amycretin, a

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching $39.3 billion, thanks to its portfolio of potent drugs for cardiometabolic illnesses like diabetes and obesity.

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated prices for Ozempic, Wegovy, and Rybelsus will be. In Medicare's negotiations for 2026, the new prices achieved an average of 22% savings.

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 products, by mimicking a hormone in the body that provides a satiated feeling and curbs hunger, but adds a different hormone in the pancreas.

Novo Nordisk scored a much-needed win on Friday, with early-stage data on a new weight-loss drug that suggested it could work better than the obesity blockbusters already on the market. Novo American depositary receipt was down 38% in the six months prior to Friday’s announcement,

The healthcare industry experienced a rollercoaster of a year in 2024, with pharmacy benefits undergoing significant shifts. Rising drug costs, advancements in medication technology, and changing coverage strategies have forced employers, health plans, and patients to navigate difficult challenges.